Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 35 Esophageal Squamous Cell Carcinoma 19 Carcinoma, Non-Small-Cell Lung 19 Carcinoma, Hepatocellular 18 Squamous Cell Carcinoma of Head and Neck 15 Triple Negative Breast Neoplasms 14 Breast Neoplasms 12 Uterine Cervical Neoplasms 11 Colorectal Neoplasms 11 Small Cell Lung Carcinoma 10 Melanoma 10 Carcinoma, Renal Cell 9 Stomach Neoplasms 8 Recurrence 8 Head and Neck Neoplasms 7 Rectal Neoplasms 5 Neoplasm Metastasis 5 Esophageal Neoplasms 5 Carcinoma, Transitional Cell 5 Advanced Solid Tumor 5 Urinary Bladder Neoplasms 4 Sarcoma 4 Pancreatic Neoplasms 4 Neoplasms 4 Liver Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4 Cholangiocarcinoma 4 Solid Tumor 3 Nasopharyngeal Neoplasms 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × toripalimab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡